These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25179915)

  • 1. A review of the pharmacological properties of insulin degludec and their clinical relevance.
    Haahr H; Heise T
    Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
    Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
    Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
    Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
    Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
    Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
    Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of insulin degludec.
    Vora J; Cariou B; Evans M; Gross JL; Harris S; Landstedt-Hallin L; Mithal A; Rodriguez MR; Meneghini L
    Diabetes Res Clin Pract; 2015 Jul; 109(1):19-31. PubMed ID: 25963320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
    Ikushima I; Kaku K; Hirao K; Bardtrum L; Haahr H
    J Diabetes Investig; 2016 Mar; 7(2):270-5. PubMed ID: 27042281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
    Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
    Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
    Biester T; Blaesig S; Remus K; Aschemeier B; Kordonouri O; Granhall C; Søndergaard F; Kristensen NR; Haahr H; Danne T
    Pediatr Diabetes; 2014 Feb; 15(1):27-33. PubMed ID: 24467565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
    Heise T; Korsatko S; Nosek L; Coester HV; Deller S; Roepstorff C; Segel S; Kapur R; Haahr H; Hompesch M
    J Diabetes; 2016 Jan; 8(1):132-8. PubMed ID: 25581159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
    Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
    Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
    Korsatko S; Deller S; Koehler G; Mader JK; Neubauer K; Adrian CL; Thomsen H; Haahr H; Pieber TR
    Clin Drug Investig; 2013 Jul; 33(7):515-21. PubMed ID: 23749405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25507175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.